BioceltixS.A.
Research and experimental development in natural sciences and engineering
Overview
Bioceltix is a Polish biotechnology company that develops innovative veterinary biological drugs, specifically using allogenic stem cells to treat conditions such as osteoarthritis in dogs and atopic dermatitis in both dogs and horses. The company focuses on immunomodulatory therapies targeting inflammatory and autoimmune diseases, adhering to high pharmaceutical quality standards. Bioceltix is also advancing a research project for a cell-free biological drug aimed at treating atopic dermatitis in dogs.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 75.10
- High
- PLN 75.90
- Low
- PLN 73.40
- Volume
- 5.76K
- Avg. vol.
- 2.58K
- Market cap
- PLN 406.62M
- P/E ratio
- —
- EPS
- -PLN 3.35
- Shares outstanding
- 5.53M
- 52-week
- PLN 73.40 – 76.00
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLBCLTX00019
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD -17.56k | USD -1.36m | USD -1.37m |
| Q1 2026 | USD 1.89k | USD -1.56m | USD -1.53m |
| Q4 2025 | USD 0.00 | USD -857.86k | USD -850.33k |
| Q3 2025 | USD 0.00 | USD -1.12m | USD -1.10m |
Results for Q3 2026:Nov 27, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-08-30. Active
22 1050 1575 1000 0090 3295 4308- 90 1050 1575 1000 0090 8693 2226
- 97 1050 1575 1000 0090 3295 4316
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 1, 2021 | Shareholders' meeting convened | |
| Dec 29, 2020 | Shareholders' meeting convened | |
| Jul 8, 2020 | Shareholders' meeting convened |
Public aid
15 public aid cases recorded, with a total value of $17,294,925.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 23, 2026 | Aid for research and development projects: industrial research | $1,364,877 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 23, 2026 | Aid for research and development projects: experimental development | $479,112 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jul 16, 2025 | Regional investment aid | $4,357,905 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
5 projects co-financed from European Funds recorded, with total EU co-financing of $12,633,260.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-10-01 | Innowacyjny bezkomórkowy lek biologiczny dla zastosowań w weterynarii (InnoBioVet) | $3,796,663 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2024-08-20 | Budowa i uruchomienie wytwórni farmaceutycznej innowacyjnych weterynaryjnych produktów leczniczych terapii zaawansowanej | $4,348,078 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2023-06-01 | Opracowanie biologicznego weterynaryjnego produktu leczniczego BCX-CM-AD przeznaczonego do leczenia atopowego zapalenia skóry u psów | $2,525,585 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations and sign on behalf of the company independently. In the case of a multi-member management board, joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy, is required to make declarations and sign on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Łukasz Piotr Bzdzion (44)  | Shareholder of a joint-stock company, 12.65% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | |
| Ecoverseasp. z o.o. | $891,022.45 | coslab.pl | |
| OrthogetS.A. | $532,980.53 | orthoget.com | |
| CTI Clinical Trial And Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | |
| VET Cell Techsp. z o.o. | $483,439.81 | vetcelltech.com | |
| BiottsS.A. | $372,115.60 | biotts.com | |
| PolbionicaS.A. | $356,011.70 | polbionica.com | |
| Green ZebrasS.A. | $328,658.91 | whygreenzebras.pl | |
| BiocamS.A. | $327,799.68 | biocam.ai | |
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl |
Change history
| Date | Event |
|---|---|
| 2025-11-06 | Share capital change (492,446.80 PLN → 538,225.30 PLN) |
| 2025-08-26 | PKD change (Removed: 10.91.Z, 20.20.Z, 46.75.Z, 72.11.Z, 72.19.Z; Added: 20.20.C, 21.20.Z, 46.85.B, 71.20.C, 72.10.Z, 77.40.B) |
| 2024-06-27 | Share capital change (412,946.80 PLN → 492,446.80 PLN) |
| 2023-07-03 | Share capital change (397,946.80 PLN → 412,946.80 PLN) |
| 2023-04-28 | Share capital change (357,946.80 PLN → 397,946.80 PLN) |
FAQ
Last updated: 2026-07-27